Baxter International (NYSE:BAX) met analyst estimates on profits, but missed on revenue, while also reaffirming guidance. Earnings rose by 4.6% to $1.14 a share and revenue was flat at $3.48 billion. Analysts expected revenue of $3.52 billion. The company expects full-year EPS in the range of $4.51-$4.54, and said it expects revenue excluding foreign-currency impact should increase by 4% to 5%.
Shares are higher by about 1.3 percent.
Yesterday, rival Abbott Laboratories (NYSE:ABT) announced third quarter profit was higher and beat analyst estimates, though revenue fell.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.